Welcome to our dedicated page for Serina Therapeutics SEC filings (Ticker: ser), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Serina Therapeutics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Serina Therapeutics's regulatory disclosures and financial reporting.
Serina Therapeutics, Inc. reported that its Board of Directors amended the company’s Amended and Restated Bylaws on August 18, 2025. The changes add safe harbor procedures for company actions or transactions where directors, officers, controlling stockholders, or control groups have interests or relationships that could make them “interested” or not independent for that matter. The amendment also supplements the existing forum selection clause in the certificate of incorporation, extending it to stockholder claims, when acting as stockholders or on behalf of the corporation, that relate to the company’s business, affairs, or the rights or powers of the company, its stockholders, directors, or officers.
Randall Moreadith, Chief Scientific Officer of Serina Therapeutics (SER), reported option exercises and immediate sales in August 2025. On 08/18/2025 she exercised 2,227 stock options at a $0.06 strike and sold the resulting shares at $5.25. On 08/20/2025 she exercised 2,077 stock options at $0.06 and sold those shares at $5.10. The filing states the stock options are fully vested. Table entries show derivative holdings after the transactions of 471,263 and 469,186 option-based underlying shares, reported as direct holdings. The reporting person signed the Form 4 on 08/20/2025.
Serina Therapeutics furnished a press release announcing its financial results for the quarter ended June 30, 2025. The current report states the press release is provided as Exhibit 99.1 and that the information is furnished, not filed, meaning it is not automatically incorporated by reference into other SEC filings.
This 8-K does not include the text of the financial results within the report itself; readers must consult Exhibit 99.1 for detailed revenue, expense, profitability or other performance metrics.
Report: Form 4 filed by Moreadith Randall (Chief Scientific Officer) for Serina Therapeutics, Inc. (SER).
Transactions (08/04/2025): The reporting person acquired 5,500 shares of common stock at $0.06 (Table I, Code M) and sold 5,500 shares of common stock at a weighted average price of $5.17 (Table I, Code S); post-transaction common stock beneficially owned: 0. Footnote states sale prices ranged $5.13–$5.35. The reporting person also holds stock options: 5,500 options exercisable through 05/06/2031 and 478,990 derivative securities beneficially owned following the reported transactions (direct). Options are reported as fully vested. Earliest transaction date: 08/04/2025; Form signed 08/05/2025.
Insider transaction summary (SEC Form 4)
On 07/28/2025, Serina Therapeutics (SER) Chief Scientific Officer Dr. Randall Moreadith exercised 6,500 stock options at a strike of $0.06 and immediately sold the resulting shares in the open market. The weighted-average sale price was $5.89 (price range $6.02–$5.60). Net of the option cost, the insider realized roughly $38 k in gross proceeds, while the company received only ~$390 from the option exercise.
After the transactions the officer now holds 0 common shares directly, but still owns 488,686 fully-vested options expiring 05/06/2031. The divestment is immaterial relative to SER’s share count and does not alter overall insider exposure, yet it removes all direct share ownership for this executive.
No other securities, derivatives or accompanying disclosures were reported.
Form 4 snapshot – Serina Therapeutics (SER): On 07/21/2025 Chief Scientific Officer Randall Moreadith exercised 6,500 fully-vested options at an exercise price of $0.06 and immediately sold the same 6,500 common shares in the open market. The weighted-average sale price was $5.34 (range $5.31-$5.40), generating gross proceeds of roughly $34.7 k and eliminating his direct common-stock position, which now stands at 0 shares. He retains 495,186 options after the transaction. The filing reflects a routine option-exercise-and-sell pattern rather than large-scale disposal, but it does reduce immediate share ownership by a named executive.